USC Clinical Trials seeks healthy volunteers for malaria study - University of the Sunshine Coast, Queensland, Australia

Accessibility links

USC News

USC Clinical Trials seeks healthy volunteers for malaria study

5 Jan 2021

USC Clinical Trials has partnered with the QIMR Berghofer Medical Research Institute in Brisbane to investigate whether an approved anti-malarial drug can be used more extensively to counter malaria – a disease that claims more than 400,000 lives worldwide each year.

While malaria is not prevalent in Australia, it is responsible for more deaths than any other parasitic disease in nearby countries like Papua New Guinea and in regions such as Africa.

New approaches to malaria control are required because malaria parasites are becoming immune to existing treatment options.

The drug being investigated by USC Clinical Trials and QIMR Berghofer is already approved in Australia for the treatment of some malaria infections.

This study is assessing whether it can be used in lower doses to help treat or prevent malaria.

USC Clinical Trials’ centre at Morayfield is hosting the phase 1 study, which runs in three parts and requires healthy volunteers – those with no medical conditions and taking no prescription medications – aged between 18 and 55.

Part 1 of the study is already underway, but further participants are needed for later parts starting early this year.

Volunteers must be willing to spend approximately five consecutive days and four nights at the clinic and attend multiple outpatient visits over a three-month period as part of the study.

USC Clinical Trials Morayfield Operations Manager Sharon Rankine said participation in this trial would involve a considerable time commitment.

She said healthy volunteers who meet the eligibility criteria and complete the study would be paid for their participation. For more details or to register interest go to

Malaria clinical trial

Related articles

Clinical trial of treatment for ulcerative colitis
17 Aug 2021

USC Clinical Trials is continuing early-phase research into an investigational treatment that aims to improve the lives of those with mild to moderate ulcerative colitis by reducing inflammation and improving the gut’s healing ability

New mRNA COVID-19 vaccine trial to begin soon
27 Jul 2021

USC Clinical Trials will soon begin a trial of a potential new mRNA vaccine formulation for COVID-19 at its Morayfield centre.

Clinical trial of needle-free vaccine delivery technology
26 May 2021

USC Clinical Trials is about to begin a study in collaboration with Australian biotechnology company Vaxxas, developers of a potential new needle-free vaccine delivery technology – the high-density microarray patch (HD-MAP).

Contact the USC media team

Name Position Email Phone
Terry Walsh Manager, Media and Messaging +61 7 5430 1160
Clare McKay Media Relations Officer (Regional) +61 7 5456 5669

Search results for

Recent news